166 related articles for article (PubMed ID: 17575222)
1. Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on radiation therapy oncology group protocol 92-02.
Khor LY; Moughan J; Al-Saleem T; Hammond EH; Venkatesan V; Rosenthal SA; Ritter MA; Sandler HM; Hanks GE; Shipley WU; Pollack A
Clin Cancer Res; 2007 Jun; 13(12):3585-90. PubMed ID: 17575222
[TBL] [Abstract][Full Text] [Related]
2. Bcl-2 and bax expression and prostate cancer outcome in men treated with radiotherapy in Radiation Therapy Oncology Group protocol 86-10.
Khor LY; Desilvio M; Li R; McDonnell TJ; Hammond ME; Sause WT; Pilepich MV; Okunieff P; Sandler HM; Pollack A
Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):25-30. PubMed ID: 16814949
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202.
Chakravarti A; DeSilvio M; Zhang M; Grignon D; Rosenthal S; Asbell SO; Hanks G; Sandler HM; Khor LY; Pollack A; Shipley W;
J Clin Oncol; 2007 Jul; 25(21):3082-9. PubMed ID: 17634487
[TBL] [Abstract][Full Text] [Related]
4. COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial.
Khor LY; Bae K; Pollack A; Hammond ME; Grignon DJ; Venkatesan VM; Rosenthal SA; Ritter MA; Sandler HM; Hanks GE; Shipley WU; Dicker AP
Lancet Oncol; 2007 Oct; 8(10):912-20. PubMed ID: 17881290
[TBL] [Abstract][Full Text] [Related]
5. Biochemical failure and the temporal kinetics of prostate-specific antigen after radiation therapy with androgen deprivation.
Buyyounouski MK; Hanlon AL; Horwitz EM; Uzzo RG; Pollack A
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1291-8. PubMed ID: 15817330
[TBL] [Abstract][Full Text] [Related]
6. The importance of protein kinase A in prostate cancer: relationship to patient outcome in Radiation Therapy Oncology Group trial 92-02.
Pollack A; Bae K; Khor LY; Al-Saleem T; Hammond ME; Venkatesan V; Byhardt RW; Asbell SO; Shipley WU; Sandler HM
Clin Cancer Res; 2009 Sep; 15(17):5478-84. PubMed ID: 19706804
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of abnormal p53 expression in locally advanced prostate cancer treated with androgen deprivation and radiotherapy: a study based on RTOG 9202.
Che M; DeSilvio M; Pollack A; Grignon DJ; Venkatesan VM; Hanks GE; Sandler HM;
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1117-23. PubMed ID: 17689883
[TBL] [Abstract][Full Text] [Related]
8. Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x.
Pollack A; Cowen D; Troncoso P; Zagars GK; von Eschenbach AC; Meistrich ML; McDonnell T
Cancer; 2003 Apr; 97(7):1630-8. PubMed ID: 12655519
[TBL] [Abstract][Full Text] [Related]
9. Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02.
Pollack A; DeSilvio M; Khor LY; Li R; Al-Saleem TI; Hammond ME; Venkatesan V; Lawton CA; Roach M; Shipley WU; Hanks GE; Sandler HM
J Clin Oncol; 2004 Jun; 22(11):2133-40. PubMed ID: 15169799
[TBL] [Abstract][Full Text] [Related]
10. Expression of Bcl-2 and Bax in advanced or metastatic prostate carcinoma.
Anvari K; Seilanian Toussi M; Kalantari M; Naseri S; Karimi Shahri M; Ahmadnia H; Katebi M; Sedighi Pashaki A; Dayani M; Broumand M
Urol J; 2012; 9(1):381-8. PubMed ID: 22395836
[TBL] [Abstract][Full Text] [Related]
11. Prospective Validation of Diagnostic Tumor Biomarkers in Men Treated With Radiotherapy for Prostate Cancer.
Pollack A; Kwon D; Walker G; Khor LY; Horwitz EM; Buyyounouski MK; Stoyanova R
J Natl Cancer Inst; 2017 Feb; 109(2):1-8. PubMed ID: 28376214
[TBL] [Abstract][Full Text] [Related]
12. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer.
Horwitz EM; Bae K; Hanks GE; Porter A; Grignon DJ; Brereton HD; Venkatesan V; Lawton CA; Rosenthal SA; Sandler HM; Shipley WU
J Clin Oncol; 2008 May; 26(15):2497-504. PubMed ID: 18413638
[TBL] [Abstract][Full Text] [Related]
13. Long-term hormone therapy and radiation is cost-effective for patients with locally advanced prostate carcinoma.
Konski A; Watkins-Bruner D; Brereton H; Feigenberg S; Hanks G
Cancer; 2006 Jan; 106(1):51-7. PubMed ID: 16323171
[TBL] [Abstract][Full Text] [Related]
14. Retrospective evaluation reveals that long-term androgen deprivation therapy improves cause-specific and overall survival in the setting of dose-escalated radiation for high-risk prostate cancer.
Feng FY; Blas K; Olson K; Stenmark M; Sandler H; Hamstra DA
Int J Radiat Oncol Biol Phys; 2013 May; 86(1):64-71. PubMed ID: 23462420
[TBL] [Abstract][Full Text] [Related]
15. MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02.
Khor LY; Bae K; Paulus R; Al-Saleem T; Hammond ME; Grignon DJ; Che M; Venkatesan V; Byhardt RW; Rotman M; Hanks GE; Sandler HM; Pollack A
J Clin Oncol; 2009 Jul; 27(19):3177-84. PubMed ID: 19470936
[TBL] [Abstract][Full Text] [Related]
16. Long-term androgen deprivation increases Grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy.
Feigenberg SJ; Hanlon AL; Horwitz EM; Uzzo RG; Eisenberg D; Pollack A
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):397-405. PubMed ID: 15890581
[TBL] [Abstract][Full Text] [Related]
17. Long-term results after high-dose radiotherapy and adjuvant hormones in prostate cancer: how curable is high-risk disease?
Zapatero A; García-Vicente F; Martín de Vidales C; Cruz Conde A; Ibáñez Y; Fernández I; Rabadán M
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1279-85. PubMed ID: 20932659
[TBL] [Abstract][Full Text] [Related]
18. bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer.
Mackey TJ; Borkowski A; Amin P; Jacobs SC; Kyprianou N
Urology; 1998 Dec; 52(6):1085-90. PubMed ID: 9836559
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer DNA ploidy and response to salvage hormone therapy after radiotherapy with or without short-term total androgen blockade: an analysis of RTOG 8610.
Pollack A; Grignon DJ; Heydon KH; Hammond EH; Lawton CA; Mesic JB; Fu KK; Porter AT; Abrams RA; Shipley WU
J Clin Oncol; 2003 Apr; 21(7):1238-48. PubMed ID: 12663710
[TBL] [Abstract][Full Text] [Related]
20. Late Radiation and Cardiovascular Adverse Effects After Androgen Deprivation and High-Dose Radiation Therapy in Prostate Cancer: Results From the DART 01/05 Randomized Phase 3 Trial.
Zapatero A; Guerrero A; Maldonado X; Álvarez A; González-San Segundo C; Cabeza Rodriguez MA; Macías V; Pedro Olive A; Casas F; Boladeras A; Martín de Vidales C; Vázquez de la Torre ML; Calvo FA
Int J Radiat Oncol Biol Phys; 2016 Oct; 96(2):341-348. PubMed ID: 27598804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
